Zacks
0
All posts from Zacks
Zacks in Our Research. Your Success.,

Becton, Dickinson (BDX) Beats Q2 Earnings & Sales

Based in New Jersey, Becton, Dickinson and Company BDX is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. These products are used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
 
Currently, Becton, Dickinson has a Zacks Rank #3 (Hold) but that could change following its second-quarter fiscal 2016 earnings report which has just released. We have highlighted some of the key details from the just-released announcement below:
 
Earnings: Becton, Dickinson’s adjusted earnings of $2.18 per share beat the Zacks Consensus Estimate by 17 cents and increased 44.7% year-over-year on a currency-neutral basis.
 
Revenues: Adjusted revenues amounted to $3.07 billion, up 55.2% from the year-ago quarter on a currency-neutral basis. Revenues beat the Zacks Consensus Estimate of $3.06 billion.

Key Stats: BD Medical generated revenues of $2.14 billion, up 99.5% on a year-over-year basis. BD Lifesciences generated revenues of $936 million, up 3.4% from the year-ago quarter.

Major Factors: On a comparable basis, adjusted U.S. revenues increased 5.7%. International revenues increased 4.8% on a currency-neutral basis in the reported quarter.
 
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
 
Check back later for our full write up on this Becton, Dickinson and Company earnings report later!
 

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
BECTON DICKINSO (BDX): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research